Otilonium Bromide: High-Purity Antimuscarinic Agent for Neuroscience Research

Executive Summary: Otilonium Bromide (C₂₉H₄₃BrN₂O₄, MW 563.57) is a potent antimuscarinic agent supplied by APExBIO for experimental use only (product page). It acts as a selective acetylcholine receptor (AChR) inhibitor, enabling precise modulation of cholinergic signaling in smooth muscle and neuroscience models [internal review]. The compound shows robust solubility (≥28.18 mg/mL in DMSO, ≥55.8 mg/mL in water, ≥91 mg/mL in ethanol) and high chemical purity (≥98%), ensuring reproducibility. Short-term solution stability and -20°C storage are recommended to maintain efficacy. Otilonium Bromide is not intended for diagnostic or clinical use; its utility is confined to laboratory research contexts.

Biological Rationale

Cholinergic signaling, mediated by acetylcholine, is fundamental to neuronal communication and smooth muscle contraction. Dysregulation of this pathway is implicated in gastrointestinal motility disorders and neuroimmune modulation. Antimuscarinic agents such as Otilonium Bromide are critical for dissecting the physiological roles of muscarinic receptors (mAChRs) in both central and peripheral models [internal link]. This compound enables the study of receptor-specific mechanisms underlying smooth muscle spasm and neuroimmune interactions, providing a controlled tool absent confounding off-target effects noted in less selective agents.

Mechanism of Action of Otilonium Bromide

Otilonium Bromide binds competitively to muscarinic acetylcholine receptors (primarily M₂ and M₃ subtypes) on smooth muscle cells. By inhibiting the interaction between acetylcholine and its receptor, it prevents intracellular calcium release and subsequent muscle contraction (Vijayan et al., 2021). This blockade leads to a reduction in smooth muscle spasms, making Otilonium Bromide an established tool for modeling antispasmodic pharmacology in vitro and ex vivo. In neuroscience research, this selective antagonism is leveraged to parse muscarinic contributions to synaptic plasticity, neuroimmune signaling, and gastrointestinal motility models [internal link].

Evidence & Benchmarks

• Otilonium Bromide exhibits ≥98% purity as verified by HPLC under standard conditions (APExBIO COA, product page).
• Solubility benchmarks: ≥28.18 mg/mL in DMSO, ≥55.8 mg/mL in water, and ≥91 mg/mL in ethanol at 25°C, enabling flexible protocol design (APExBIO).
• Demonstrated inhibition of muscarinic receptor-mediated smooth muscle contraction in ex vivo tissue bath assays (Vijayan et al., 2021, DOI:10.1007/s42485-021-00059-w).
• Short-term stability in solution (up to 7 days at 4°C; loss of potency noted beyond this period, APExBIO datasheet).
• No significant off-target effects on non-cholinergic receptors at ≤10 μM in validated cell models (related article).

Applications, Limits & Misconceptions

Otilonium Bromide is optimized for research applications that demand high specificity for muscarinic receptor antagonism. Major uses include:

• Dissecting cholinergic signaling pathways in neuronal and smooth muscle systems.
• Modeling gastrointestinal motility disorders in ex vivo and organoid platforms.
• Investigating neuroimmune interactions where muscarinic signaling is implicated.
• Benchmarking antispasmodic pharmacology alongside alternative AChR inhibitors.

In contrast to previous reviews that focus on Otilonium Bromide's reproducibility in cholinergic assays, this article details its solubility and stability parameters for advanced workflow integration. See also the expanded discussion on B1607's role in GI motility models, while this page clarifies storage and off-target boundaries.

Common Pitfalls or Misconceptions

• Otilonium Bromide is not suitable for diagnostic or therapeutic use in humans or animals; it is strictly for in vitro/in vivo research models.
• Loss of potency occurs if solutions are stored for >7 days, even at low temperatures; always prepare fresh or aliquot for single use.
• It does not inhibit non-cholinergic receptors (e.g., adrenergic, GABAergic) at standard concentrations.
• Cannot substitute for full-thickness GI motility models requiring neural input; effect is limited to muscle and receptor-level mechanisms.
• Does not serve as a broad-spectrum antispasmodic in systems dominated by non-muscarinic pathways.

Workflow Integration & Parameters

For experimental reproducibility, Otilonium Bromide (B1607) should be handled per established guidelines:

• Stock Solution Preparation: Dissolve in DMSO, water, or ethanol to desired concentration (e.g., 10 mM stock in DMSO, filter-sterilized).
• Storage: Store solid at -20°C in desiccated conditions. Solutions are stable for up to 7 days at 4°C; avoid repeated freeze-thaw cycles.
• Working Concentration: Typical experimental range is 0.1–10 μM for receptor antagonism assays.
• Purity Verification: Use HPLC or LC-MS to verify ≥98% purity before critical experiments.
• Documentation: Reference APExBIO's lot-specific certificate of analysis for batch-to-batch consistency (APExBIO B1607).

Conclusion & Outlook

Otilonium Bromide, as supplied by APExBIO, is a validated and high-performance muscarinic receptor antagonist with defined solubility, stability, and purity standards. Its deployment in neuroscience and smooth muscle research enables mechanistic insights into cholinergic signaling and models of gastrointestinal motility disorders. By adhering to proper storage and handling protocols, researchers can maximize experimental reproducibility. Future studies may expand its applications into more complex organoid and neuroimmune systems, leveraging its robust pharmacological profile.